Tema Etfs LLC Increases Holdings in IDEXX Laboratories, Inc. $IDXX

Tema Etfs LLC increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 165.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,085 shares of the company’s stock after purchasing an additional 3,167 shares during the quarter. Tema Etfs LLC’s holdings in IDEXX Laboratories were worth $3,249,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in IDXX. Arkadios Wealth Advisors purchased a new position in shares of IDEXX Laboratories during the second quarter valued at approximately $405,000. Orion Porfolio Solutions LLC lifted its stake in shares of IDEXX Laboratories by 116.6% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 10,718 shares of the company’s stock worth $5,749,000 after acquiring an additional 5,770 shares during the last quarter. USA Financial Formulas bought a new stake in shares of IDEXX Laboratories during the 3rd quarter worth approximately $2,381,000. Beacon Investment Advisory Services Inc. boosted its holdings in IDEXX Laboratories by 15.7% during the 3rd quarter. Beacon Investment Advisory Services Inc. now owns 56,241 shares of the company’s stock valued at $35,932,000 after acquiring an additional 7,616 shares during the period. Finally, Baader Bank Aktiengesellschaft bought a new position in IDEXX Laboratories in the 2nd quarter valued at $415,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the sale, the executive vice president owned 21,149 shares of the company’s stock, valued at approximately $14,874,937.66. This trade represents a 30.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Up 0.1%

Shares of IDEXX Laboratories stock opened at $713.35 on Monday. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.18 and a quick ratio of 0.87. The stock has a market cap of $56.96 billion, a price-to-earnings ratio of 56.57, a PEG ratio of 3.81 and a beta of 1.67. The firm’s 50-day moving average is $706.93 and its two-hundred day moving average is $644.64. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.08. The firm had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. The company’s revenue was up 13.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on IDXX shares. JPMorgan Chase & Co. lifted their target price on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Wall Street Zen raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 3rd. Jefferies Financial Group reiterated a “buy” rating and set a $830.00 price objective on shares of IDEXX Laboratories in a report on Tuesday, November 4th. BTIG Research upped their target price on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Finally, UBS Group raised their target price on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $763.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.